Galleri Review

Galleri is a multi-cancer early detection (MCED) blood test developed by GRAIL. Instead of imaging an organ or screening for one cancer at a time, it analyzes cell-free DNA methylation patterns in a blood sample and looks for signals from 50+ different cancers — including pancreatic, ovarian and esophageal, none of which have a standard screening test for the general population. It is physician-ordered rather than directly consumer-purchasable, and it lists at roughly $949 per test.

The number that defines the product is not the price. It is the pair of accuracy figures: specificity around 99.5% and overall sensitivity around 52% across all stages. Those two numbers mean a positive result is worth acting on immediately and a negative result changes almost nothing about the rest of your screening schedule. This review covers the methodology, what the $949 does and does not buy, how ordering and the blood draw actually work, and where imaging or standard screening is the better purchase.

Public litigation

GRAIL (maker of Galleri) is named alongside Illumina in a federal securities class action over the Illumina–GRAIL acquisition and related Galleri claims (In re Illumina, S.D. Cal.). The complaint was dismissed without prejudice in 2025 and plaintiffs refiled. This is investor litigation, not a consumer product-injury suit. Allegations only — CourtListener dismissal order; Cancer Letter on amended complaint.

Scorecard

What you get for the money

Galleri is a single laboratory test, not a program. The $949 buys analysis and a report; every step before and after that sits with a clinician.

• Methylation analysis of cell-free DNA. Bundled. The lab sequences fragments of DNA shed into the bloodstream and reads their methylation patterns rather than their mutations.
• Screening across 50+ cancer types. Bundled. One draw covers the full panel; there is no per-cancer add-on to buy.
• Cancer signal origin prediction. Bundled, and only relevant on a positive. The report names the predicted tissue of origin so the workup starts somewhere specific.
• A binary result plus context. Bundled. The report states whether a cancer signal was detected, with the origin prediction where applicable.
• Physician ordering. Required, and bundled only in some channels. Telehealth services and physician networks that offer Galleri may include the ordering visit or bill it separately.
• Blood draw. Typically included, at a partner draw site or via mobile phlebotomy depending on market.
• Not included: any diagnostic workup. Imaging, endoscopy and biopsy after a positive result are ordered and billed by other providers.
• Not included: general biomarkers. This is a cancer-signal test only. It reports nothing about lipids, glucose, hormones, kidney function or inflammation.

What it costs

The list price is stable across most channels at roughly $949, and it is not insurance-covered for asymptomatic screening at this time. Employer benefit programs and some physician practices offer bundled pricing, which is worth asking about because the discount is on access rather than on the test itself.

HSA and FSA eligibility varies by plan administrator. The cost most buyers fail to model is the workup after a detected signal: at ~99.5% specificity the false-positive rate is low, but a positive result reliably triggers imaging or endoscopy, and that spend is separate from the $949.

Signing up and the first visit

The ordering step is the part that differs from every consumer test in this category. You cannot buy Galleri from a website and have a kit mailed to you. A licensed clinician has to order it, which in practice means one of three routes: your own physician, a telehealth service that includes Galleri ordering in a consultation, or an employer benefit program that has contracted for it.

Once ordered, the collection is a single standard venous blood draw — two tubes, a few minutes, at a partner draw site or with a mobile phlebotomist depending on your market. No fasting is required and no imaging is involved. This is the practical advantage over MRI-based screening: there is no scanner, no bore, no hour of lying still, and no eligibility exclusion for pacemakers, implants or claustrophobia.

Turnaround is generally a couple of weeks from draw to report, longer than a routine blood panel because the sequencing and classification pipeline is not a same-day assay. The report itself is short. It states whether a cancer signal was detected, and if one was, it names one or two predicted tissues of origin ranked by likelihood. Results go back to the ordering clinician, who is the person responsible for telling you what happens next — which is why choosing an ordering route where someone will actually take that call matters more than saving a consult fee.

What the test detects

Methylation patterns differ between healthy tissue and tumor tissue, and they also differ between tissue types. That is the mechanism behind both halves of the product: detecting that a cancer signal is present, and predicting where it came from.

• Cancers with no standard screening test. Pancreatic, ovarian and esophageal cancers are the headline cases. There is no population-wide mammogram-equivalent for any of them, and they are typically found late.
• Cancers with existing screening, as a second layer. Signals from colorectal, breast, lung and other screened cancers can appear, but the established modality remains the standard of care for each.
• Cancer signal origin. On a positive result, the predicted tissue of origin directs the workup — targeted imaging or endoscopy of a named site rather than a blind search.
• Stage sensitivity gradient. Detection improves as stage advances. Sensitivity at stage I is well below the ~52% all-stage figure, which is the limitation that matters most for a test sold on early detection.
• Intended population. Adults 50+, or younger adults with elevated risk from family history, prior cancer, or a known genetic predisposition.

Two named exceptions are worth knowing before you order. The test is not designed for people with an active cancer diagnosis or currently undergoing cancer treatment — it is a screening tool for the asymptomatic, not a monitoring tool. And clonal hematopoiesis, a common age-related expansion of blood-cell clones, is a recognized source of ambiguity in cell-free DNA assays generally, which is one reason results return to a clinician rather than straight to you.

Strengths

• Very high specificity (~99.5%). False positives are rare, so a positive result carries real weight and justifies moving straight to workup.
• Reaches cancers nothing else screens. Pancreatic, ovarian and esophageal cancers have no standard screening test; this is the clearest source of added coverage.
• Cancer signal origin prediction. A positive result points at a tissue, so the diagnostic workup starts targeted rather than searching blind.
• One blood draw, no imaging. No scanner time, no radiation, no contrast, and none of the implant or claustrophobia exclusions that disqualify people from MRI screening.
• Complements rather than duplicates imaging. A methylation signal and an MRI finding are different classes of evidence, so layering the two adds coverage instead of repeating it.
• Clinician in the loop by design. Physician ordering means a qualified person receives the result and owns the next step, which is not true of consumer-ordered screening.

Trade-offs

• Sensitivity limitations at early stage. Overall sensitivity is ~52% across all stages and materially lower at stage I, exactly where treatment is most effective.
• A negative result reassures more than it should. Roughly half of cancers present in a tested population are not detected, so the main behavioral risk is a patient skipping established screening after a clean report.
• Price. ~$949 per test, not insurance-covered for asymptomatic screening, with annual repetition marketed.
• Physician ordering required. An extra step, an extra potential fee, and a barrier for anyone without a clinician relationship.
• Does not replace standard screening. Mammograms, colonoscopies, cervical screening and low-dose lung CT remain the standard of care for their cancers.
• Population-scale benefit still under study. Ongoing trials including NHS-Galleri are evaluating whether MCED screening reduces cancer mortality at scale; that question is not yet settled.

How it compares

The table lists Galleri alongside its closest peers in the screening cluster, listed alphabetically, with the same four criteria applied to every row. Ezra and Prenuvo are imaging products and are best read as complements to Galleri rather than substitutes — they find structure, this finds signal. Fountain Life is the bundled option, where screening sits inside a concierge membership with biomarkers and a physician attached.

The practical read: Galleri is the cheapest entry in this cluster at roughly $949 and the only one that requires a clinician to order it. Ezra and Prenuvo cost more, cover anatomy Galleri cannot see, and miss cancer signals Galleri can. Buyers who can afford both frequently run both, because the overlap between what a methylation assay detects and what an MRI visualises is small. Fountain Life assembles that stack for you inside a membership starting above $19,500 a year, which buys the coordination as much as the tests.

Who should buy it — and who should not

Buy it if:

• You are 50 or older, where cancer incidence rises enough that the pre-test probability makes a screening test meaningfully more informative.
• You have a family history of a cancer with no standard screening test — pancreatic and ovarian are the recurring cases.
• You have a known genetic predisposition or a prior cancer history, and your clinician wants broader surveillance than organ-by-organ screening provides.
• You already keep up with colonoscopy, mammogram, cervical screening and lung CT as indicated, and want to add coverage on top rather than replace any of it.

Look elsewhere if:

• Your concern is structural rather than oncologic — an aneurysm, a spine problem, an unexplained mass — buy an Ezra or Prenuvo whole-body MRI instead, which images anatomy this test cannot see.
• You want screening embedded in a program where a physician acts on every finding — buy a Fountain Life membership instead and price the full year.
• You are behind on standard screening — buy the colonoscopy, mammogram or low-dose lung CT first, because those carry mortality-benefit evidence that MCED testing has not yet established.
• You are currently diagnosed with or being treated for cancer — this is a screening test for asymptomatic adults, and your oncology team's monitoring plan is the right tool instead.

Retesting and what year two costs

Annual retesting is the marketed cadence, and unlike imaging there is no exposure argument against repeating a blood draw. The case for annual repetition rests on catching a signal that emerged since the last draw. The case against it is the same arithmetic as the first test: at ~52% all-stage sensitivity, a repeat negative still leaves a substantial share of cancers undetected, so the second test does not buy the reassurance its cadence implies.

Pricing does not change with repetition. Year two is roughly $949 again, plus any consult fee your ordering route charges, with no published multi-year rate. Two years of annual testing is therefore roughly $1,900 before any workup — comparable to a single whole-body MRI at the upper end of Prenuvo's range, which is a useful way to frame the trade if you are choosing between the two rather than stacking them.

What the renewal actually includes is identical to the first test: the same panel, the same methylation analysis, the same report format. There is no expanding panel and no accumulated trend line, because a cancer-signal test is binary rather than a biomarker you track. If you want a screening spend that produces a trend over time, an annual biomarker panel does that and this does not. The reasonable cadence for most people is annual only while an elevated-risk factor is present, and a clinician-set interval otherwise.

Related

• Prenuvo review — imaging-based screening
• Ezra review — imaging-based screening
• Fountain Life review — bundles imaging + biomarkers
• Doctor-led options — every physician-supervised program compared
• All platform reviews